Singapore National Eye Centre
snec.com.sgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
84
Active
13
Phase 3
7
Total enrollment
8,751
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atropine sulfate 0.01% | — | — | — | — | — | 1 | |
| Faricimab | — | — | — | — | 2 | ||
| Atropine 0.025% | — | — | — | — | — | 1 | |
| Ranibizumab | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2028-12-31
- 2029-06
- 2029-08
Top conditions
- Dry Eye14
- Myopia14
- Glaucoma7
- Polypoidal Choroidal Vasculopathy4
- Dry Eyes4
- Age Related Macular Degeneration3
- Pterygium3
- Pachychoroid Disease3
Frequently asked questions about Singapore National Eye Centre
- How many clinical trials does Singapore National Eye Centre have on ClinicalTrials.gov?
- Singapore National Eye Centre is listed as the lead sponsor on 84 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Singapore National Eye Centre's trials are in Phase 3?
- 7 of Singapore National Eye Centre's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Singapore National Eye Centre focus on?
- Singapore National Eye Centre's most-studied conditions on ClinicalTrials.gov are Dry Eye, Myopia, Glaucoma, Polypoidal Choroidal Vasculopathy, Dry Eyes.
- When are Singapore National Eye Centre's next clinical trial readouts?
- Singapore National Eye Centre has 4 upcoming primary-completion readouts tracked here; the soonest is “The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)”, expected around 2024-12-31.